1 TAFAZZIN REGULATES NEUTROPHIL MATURATION AND INFLAMMATORY

2 **RESPONSE**

Przemysław Zakrzewski^{1, 5}, Christopher M. Rice^{1, 5}, Kathryn Fleming¹, Drinalda Cela¹, Sarah
J. Groves¹, Fernando Ponce¹, Willem Gibbs¹, Kiran Roberts², Tobias Pike¹, Douglas
Strathdee³, Eve Anderson³, Angela H. Nobbs⁴, Ashley Toye², Colin Steward¹ and Borko
Amulic^{1,6}

- 7 1. School of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
- 8 2. School of Biochemistry, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
- 9 3. Cancer Research UK Scotland Institute, Glasgow, G61 1BD, UK
- 10 4. Bristol Dental School Research Laboratories, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
- 11 5. Contributed equally
- 12 6. Corresponding author
- 13 <u>Correspondence to</u>: borko.amulic@bristol.ac.uk

14 ABSTRACT

Barth syndrome (BTHS) is a rare genetic disease caused by mutations in 15 the TAFAZZIN gene. It is characterized by neutropenia, cardiomyopathy and skeletal 16 myopathy. Neutropenia in BTHS is associated with life-threatening infections, yet there 17 is little understanding of the molecular and physiological causes of this phenomenon. 18 We combined bone marrow analysis, CRISPR/Cas9 genome editing in hematopoietic 19 stem cells and functional characterization of circulating BTHS patient neutrophils to 20 investigate the role of TAFAZZIN in neutrophils and their progenitors. We demonstrate 21 a partial cell intrinsic differentiation defect, along with a dysregulated neutrophil 22 inflammatory response in BTHS, including elevated formation of neutrophil 23 extracellular traps (NETs) in response to calcium flux. Developmental and functional 24 alterations in BTHS neutrophils are underpinned by perturbations in the unfolded 25 protein response (UPR) signaling pathway, suggesting potential therapeutic avenues 26 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. for targeting BTHS neutropenia. 27

28 **INTRODUCTION**

Barth syndrome (BTHS) is a rare X-linked genetic disease characterized principally by 29 dilated cardiomyopathy, skeletal myopathy, and neutropenia [1-3]. Mutations in the 30 TAFAZZIN gene, encoding a mitochondrial lipid transacylase, are the primary cause 31 of BTHS [4]. Tafazzin is essential for remodeling and maturation of cardiolipin (CL), a 32 33 major phospholipid of the mitochondrial inner membrane, which has a crucial role in maintaining mitochondrial structure and function [2, 5]. TAFAZZIN mutations lead to 34 an accumulation of an intermediate CL species, monolysocardiolipin (MLCL), 35 impairing mitochondrial metabolism and contributing to defects in cardiomyocytes and 36 skeletal muscle, which have abundant mitochondria and are dependent on efficient 37 oxidative respiration [6]. Apart from regulating ATP generation, CL has been 38 implicated in signaling [7, 8], control of apoptosis [8, 9], generation of mitochondrial 39 reactive oxygen species (ROS) [9], and regulation of calcium homeostasis [10]. 40 Furthermore, mitochondria are important regulators of inflammation, and it has been 41 suggested that dysregulated inflammatory response is a component of BTHS [11], 42 although there is a major lack of knowledge on the innate immune response in 43 patients. Neutropenia and neutrophil-mediated inflammation are possible targets for 44 therapeutic interventions, to improve patient wellbeing and survival. 45

Neutropenia is detected in approximately 84% of BTHS patients and shows various patterns [1, 3, 12], including intermittent and unpredictable, chronic or severe, or truly cyclical [12]. Neutrophils kill microbes by phagocytosis, generation of ROS, release of antimicrobial proteins stored in secretory granules, and formation of neutrophil extracellular traps (NETs), which consist of externalized chromatin decorated with antimicrobial proteins [13]. NETs can trap microbes and prevent their dissemination but are also sensed by other innate and adaptive immune cells, leading to

proinflammatory cytokine production and propagation of inflammation [14].
Importantly, neutropenia in BTHS is associated with various bacterial infections, which
are the second leading cause of death in these patients [1].

56 Despite the prominence of neutropenia in BTHS patients, there is little understanding 57 of the molecular and physiological causes of this phenomenon [12]. Neutropenia can 58 result from defects in neutrophil production in the bone marrow, elevated apoptosis or 59 from enhanced removal of activated neutrophils from the circulatory system [15-17].

60 Limited investigation of bone marrow in BTHS led to conflicting reports: hypocellularity and reduced myeloid maturation were detected in some BTHS patients without a clear 61 block in neutrophil maturation [12, 18], and short-term colony assays using 62 63 hematopoietic stem cells (HSCs) purified from patient blood failed to detect any defects in neutrophil differentiation in vitro [18, 19]. One study described elevated 64 annexin V binding in circulating BTHS neutrophils, without increased apoptosis or 65 66 phagocytic clearance by macrophages [19]. On the other hand, studies using shRNAmediated TAFAZZIN knockdown in myeloid cell lines demonstrated increased 67 caspase-3 activation, release of cytochrome c from mitochondria, and accelerated 68 apoptosis in response to tafazzin deficiency [20]. There is therefore no consensus on 69 the mechanism of neutropenia in BTHS patients. 70

In mice, tafazzin deficiency causes embryonic lethality in C57BL/6 mice [21, 22], although other genetic backgrounds are viable. Immortalization of murine embryonic *Tafazzin*-KO myeloid progenitors demonstrated normal differentiation into mature neutrophils, normal mitochondrial electron transport chain assembly, and equivalent functional responses to wild-type (WT) cells [23]. The study did, however, detect slightly enhanced susceptibility to apoptosis upon Bcl-2 inhibition and subtle

perturbations in expression of unfolded protein response (UPR) genes, raising the
 possibility that ER-mediated stress may affect viability of BTHS cells [23].

To address the gap in understanding of BTHS neutropenia, we combined patient bone 79 marrow analysis with our recently developed ex vivo neutrophil differentiation system 80 [24] to investigate the role of TAFAZZIN in neutrophil development from HSCs. We 81 82 also performed a comprehensive analysis of neutrophil phenotype and function in BTHS patients, including proteomic analysis. Our work reveals a partial block in 83 neutrophil differentiation and maturation in BTHS, accompanied by elevated 84 intercellular calcium, hyperdegranulation, and evidence of enhanced NET formation. 85 We detect alterations in the UPR pathway and propose that this may be a potential 86 cause of the observed defects in BTHS neutrophils. 87

89 **RESULTS**

90 Partial block in bone marrow neutrophil maturation in BTHS

91 We examined neutrophil morphology in bone marrow aspirates of 5 BTHS patients (4-24 years old; all treated with G-CSF). The samples had similar features and were 92 characterized by normocellularity, normal megakaryopoiesis and erythropoiesis, and 93 unaffected eosinophil lineage (Fig. 1A, S1A). As expected with G-CSF treatment, all 94 samples exhibited marked 'left shift' i.e. an elevated number of granulocyte precursors 95 96 - promyelocytes and myelocytes. However, there was a notable decrease in the number of metamyelocytes and mature neutrophils compared to values observed in 97 healthy individuals; this was reflected in substantially reduced myeloid to erythroid 98 99 ratio (Fig. 1B). These findings demonstrate a defect in neutrophil maturation in BTHS, 100 as previously suggested [12, 18].

101 Impaired ex vivo terminal differentiation and maturation of BTHS neutrophils

To date, there have been no studies of maturation of tafazzin deficient neutrophils 102 using primary human progenitors. Our laboratory recently optimized a protocol to 103 104 differentiate human neutrophils from CD34⁺ HSCs isolated from a small amount of peripheral blood (Fig. 1C, adapted from [24]). This protocol vields approximately 50% 105 mature neutrophils, defined as CD66b⁺CD15⁺ cells. We used this system to compare 106 neutrophil differentiation from CD34⁺ progenitors of healthy control (HC) and BTHS 107 patients, recruited from the NHS National Barth Syndrome Service at Bristol Royal 108 Hospital for Children. We did not observe any difference in total cell number over 17 109 days of cell differentiation (Fig. 1D) or in proliferation ratio of BTHS and HC cells (fold 110 change from day 3: HC = 90 ± 37 vs. BTHS = 82 ± 88); (Fig 1E). Moreover, there was 111 no increase in apoptosis or necrosis in a subset of BTHS cultured neutrophils (Fig. 112

S1B) or any evident morphological changes (Fig. S1C). However, flow cytometry (Fig. 113 S1D) uncovered an average 13.4% drop in the number of differentiated CD66b⁺CD15⁺ 114 neutrophils (HC = $48.08 \pm 10.30\%$ vs. BTHS = $34.69 \pm 9.68\%$; p = 0.0145); (Fig. 1F) and 115 a 31% decrease in relative expression of the maturity marker CD11b in BTHS samples 116 $(HC = 1.00 \pm 0.25 \text{ vs. BTHS} = 0.69 \pm 0.32; \text{ p} = 0.0425);$ (Fig. 1G). Importantly, this 117 reduction was also reflected by an average 12.7% drop in the number of mature 118 CD66b⁺CD15⁺CD11b^{hi} neutrophils at the end of differentiation (HC = 37.08±5.80% vs. 119 BTHS = 24.40±7.26%; p = 0.0013) (Fig. S1E). 120

To confirm a cell-intrinsic role for tafazzin in control of neutrophil differentiation, we 121 performed shRNA knockdown experiments. First, to choose an optimal shRNA 122 construct, we used the myeloid cell line PLB-985 to screen 3 vectors encoding 123 TAFAZZIN-targeting shRNA. The most consistent results were obtained with shRNA 124 3, where we observed reductions in both expression of tafazzin and expression of 125 CD11b in differentiated cells (Fig. S1F). Next, we isolated CD34⁺ HSC from healthy 126 donors and treated them with control non-targeting or TAFAZZIN-targeting shRNA, on 127 day 3 of differentiation (corresponding to non-committed progenitors), which led to an 128 approximately 45% reduction in tafazzin expression (Fig. S1G). Similarly to BTHS 129 patient cultured neutrophils, TAFAZZIN shRNA progenitors differentiated less 130 efficiently than controls, as evidenced by a 28% reduction in CD11b expression at the 131 end of differentiation (Fig. 1H). 132

Finally, to test the effect of complete tafazzin deficiency, we used CRISPR/Cas9 to target exon 3 in CD34⁺ HSCs (day 3/non-committed progenitors, n = 3), with a scrambled gRNA serving as control. Western analysis confirmed complete tafazzin knockout at day 17 of differentiation (Fig. 1I). Importantly, complete tafazzin deficiency resulted in an approximately 50% reduction in cell proliferation, compared to

scrambled control, when comparing fold expansion between days 3 and 17 (scrambled gRNA = 33 ± 15 vs. *TAFAZZIN* gRNA = 17 ± 9 , p = 0.1394) (Fig. 1J, S1H). Moreover, similarly to shRNA-treated neutrophils, tafazzin knockout cells exhibited a ~15% decrease in the expression of differentiation marker CD11b (Fig. 1K). In summary, experiments using HSC-derived neutrophils demonstrate that tafazzin has a cell autonomous role in regulating neutrophil differentiation and maturation from early progenitors and confirm a partial block in granulopoiesis in BTHS patients.

145 Immature status of circulating BTHS neutrophils

We next examined circulating neutrophils in BTHS patients (n = 15, 4/15 not receiving 146 G-CSF therapy) and healthy controls (n = 15, all untreated). Flow cytometric 147 148 immunophenotyping of neutrophil surface markers in whole blood, using previously 149 described gating strategies [25], revealed significantly reduced levels of the maturity marker CD10 (HC = 4036 ± 2343 vs. BTHS = 2168 ± 1969 ; p = 0.0253) and a trend 150 towards reduced expression of CD16 (FcYRIIIB) (HC = 20222±10030 vs. BTHS = 151 14037 \pm 9303; p = 0.0908); (Fig. 2A). We did not observe any differences in CD101 and 152 CD62L between HC and BTHS patients (Fig. S2B). Both CD10 and CD16 expression 153 were normal in G-CSF untreated BTHS patients (n=4, 'non-neutropenic patients'); 154 (Fig. S2A). It must be stressed that these patients do not suffer from documented 155 156 neutropenia, suggesting that their hematopoietic compartment is not affected. G-CSF mobilizes immature neutrophils from the bone marrow, resulting in accumulation of 157 circulating neutrophils with reduced CD10 and CD16 [26], making it difficult to 158 159 conclude whether the observed immaturity is due to G-CSF treatment or an intrinsic feature of BTHS neutrophils. 160

162 BTHS neutrophils exhibit elevated degranulation and competent bacterial killing

We next used flow cytometry to examine neutrophil surface markers associated with 163 164 activation. Interestingly, the secondary granule marker CD66b expression was significantly elevated on patient neutrophils (HC = 2385 ± 401 vs. BTHS = 4125 ± 1156 ; 165 p < 0.0001), suggesting increased *in vivo* exocytosis compared to HC (Fig. 2B). This 166 167 finding was independent of G-CSF therapy (Fig. S2C). To examine degranulation in more detail, including exocytosis of primary granules, we isolated neutrophils using 168 negative selection and quantified exposure of the primary granule marker CD63, with 169 or without stimulation with the bacterial peptide N-formylmethionine-leucyl-170 phenylalanine (fMLP). There was no significant difference in CD63 exposure in naïve 171 neutrophils. Upon fMLP stimulation, however, BTHS neutrophils (n=31) demonstrated 172 more than 1.7-fold increase in activation compared to HC (n=29); (HC = 1213 ± 700 vs. 173 BTHS = 2115±1927; p = 0.0032); (Fig. 2C). To test if elevated degranulation occurs in 174 response to live bacteria, we stimulated purified neutrophils with Streptococcus 175 pyogenes and quantified exposure of CD66b over 40 minutes of co-incubation (Fig. 176 2D). We found elevated surface levels of the secondary granule marker in naïve BTHS 177 neutrophils, confirming our in vivo findings, as well as an approximately 2-fold increase 178 upon bacterial stimulation compared to HC. Finally, we quantified plasma abundance 179 180 of MPO, a primary granule protein, and found elevated circulating MPO levels in BTHS patients compared to healthy control plasma samples (Fig. 2E). In summary, 181 neutrophils from BTHS patients are more prone to degranulation of primary and 182 secondary granules. 183

A previous report demonstrated elevated rates of phosphatidyl serine (PS) externalization in BTHS neutrophils, although these levels were lower than those typically associated with neutrophil apoptosis [19]. We stained a portion of our

neutrophils with annexin V to quantify PS surface exposure. As previously reported, we observed increased PS exposure in naïve neutrophils (HC = $3.80\pm1.48\%$ vs. BTHS = $6.31\pm2.02\%$; p = 0.0344); (Fig. 2F). To test whether elevated PS exposure in BTHS neutrophils could result from increased degranulation, we demonstrated that fMLP stimulation increases annexin V positivity approximately 3-fold both for HC and BTHS neutrophils compared to unstimulated cells (HC = $17.86\pm12.88\%$ vs. BTHS = $14.36\pm5.19\%$; not significant); (Fig. 2G).

Secondary granules contain multiple cytoadhesive molecules and augmented 194 degranulation might result in excessive endothelial interactions, leading to 195 sequestration of neutrophils in vascular beds. We therefore analyzed spleen and liver 196 histological sections from WT and *Tafazzin*-KO mice (Fig. S2D). We did not observe 197 any difference in the number of neutrophils in the vasculature and parenchyma of 198 these tissues, indicating normal levels of margination in mice under steady state 199 conditions. Interestingly, in contrast to what is observed in BTHS patients, Tafazzin-200 KO mice, on FVB (sensitive to the Friend leukemia virus) genetic background, had 201 equivalent neutrophil counts to those of WT mice, suggesting no defects in 202 hematopoiesis (Fig. S2E). 203

Next, we investigated whether neutrophils from BTHS patients show other functional 204 alterations. Using a luminol based assay, we quantified ROS production in response 205 to phorbol 12-myristate 13-acetate (PMA) and concanavalin A (con A) and found no 206 significant differences compared to HC (Fig. 2H). Moreover, we found no difference in 207 208 NETs formation with the strong soluble inducer PMA (Fig. 2I). Moreover, BTHS neutrophils phagocytosed pHrodo[™] Streptococcus pyogenes at similar rates to HC 209 neutrophils (Fig. S2F). Finally, neutrophils from BTHS patients (n=4) and HC (n=4) 210 demonstrated equivalent killing rates of opsonized S. pyogenes bacteria (Fig. 2J). In 211

summary, BTHS neutrophils display enhanced secondary and primary degranulation,
normal PMA-induced NETosis and maintain effective killing of a Gram-positive
pathogen.

215 Mitochondrial function is not affected in BTHS patient neutrophils

216 Mitochondria in BTHS patient neutrophils have not previously been studied. We found increased mitochondrial abundance in patients relative to control, quantified with 217 MitoTracker dye (HC = 1.00 ± 0.22 vs. BTHS = 1.66 ± 0.52 ; p = 0.001); (Fig. 3A). 218 219 Interestingly, BTHS patient neutrophils had reduced mitochondrial membrane potential, as evidenced by reduction of tetramethylrhodamine ethyl ester (TMRE) 220 compared to HC neutrophils (HC = $31\pm19\%$ TMRE low cells vs. BTHS = $47\pm25\%$ 221 222 TMRE low cells; p = 0.0349; (Fig. 3B), suggesting that the increased abundance may be a compensatory mechanism for impaired activity. To test this hypothesis, we used 223 Seahorse metabolic flux analysis to test respiratory chain activity in isolated BTHS 224 primary neutrophils (n = 8, 4/8 treated with G-CSF) and HC. We found no significant 225 differences in mitochondrial ATP production, basal respiration, maximal respiration, or 226 spare respiratory capacity (Fig. 3C), arguing against gross functional impairment. 227

Finally, as several studies reported elevated mitochondrial ROS (mtROS) in BTHS 228 cardiomyocytes [2, 27], we quantified mtROS in BTHS neutrophils using a MitoSOX 229 flow cytometry assay. The percentage of MitoSOX-positive cells was elevated in BTHS 230 samples, both in homeostatic conditions (HC = 19.20 ± 15.72 vs. BTHS = 31.85 ± 16.66 ; 231 p = 0.058; (Fig. 3D) and after stimulation with fMLP (HC = 11.27±5.35% vs. BTHS = 232 $30.79\pm17.46\%$; p = 0.0084); (Fig. 3E), although this difference was not observed when 233 plotting total MitoSOX MFI (Fig. S3A-B). Moreover, we did not detect any mtROS 234 differences in BTHS HSC-derived neutrophils in a limited number of samples (Fig. 235

S3C-D). In conclusion, mitochondria in GCSF-treated BTHS patients are
characterized by elevated abundance, reduced membrane potential and elevated
mtROS. However, we failed to detect significant impairment of overall mitochondrial
functionality.

240 Increased calcium-induced NETosis in BTHS neutrophils

Excessive mtROS can affect calcium homeostasis, which in turn can regulate 241 neutrophil activation [28]. As we observed increased mtROS in BTHS neutrophils, we 242 243 decided to quantify intracellular calcium level in these neutrophils using X-Rhod-1, a cell permeant dye that exhibits increased fluorescence after binding Ca²⁺. We found a 244 >2-fold increase in intracellular calcium level of circulating BTHS cells, compared to 245 246 HC neutrophils (HC = 1.00 ± 0.08 vs. BTHS = 2.33 ± 1.26 ; p = 0.0025); (Fig. 4A). To determine whether this change is caused by G-CSF therapy or a cell-intrinsic effect of 247 tafazzin deficiency, we analyzed calcium levels in HSC-derived neutrophils and 248 249 observed an almost 3-fold increase in X-Rhod-1 signal in BTHS stem cell-derived neutrophils, compared to HC (HC = 2570 ± 671 vs. BTHS = 5662 ± 1160 ; p = 0.0162); 250 (Fig. 4B). Calcium is an essential activator of neutrophil inflammatory responses [29], 251 prompting us to ask whether tafazzin deficient neutrophils have altered functional 252 responses. To test this, we utilized the calcium ionophore A23187, which induces 253 254 calcium influx across the plasma membrane and strongly activates neutrophils [30]. As expected, A23187 induced strong degranulation of primary granules, but we did 255 not observe any significant differences in CD63 surface exposure between control and 256 257 tafazzin CRISPR/Cas9 knockout HSC-derived neutrophils (Fig. 4C).

We next investigated NET formation in tafazzin knockout HSC-derived neutrophils in response to calcium-independent (PMA) and calcium-dependent stimuli (A23187), using a live cell imaging assay. There was no difference in chromatin release in
response to PMA (Fig. 4D). On the other hand, A23187-induced NETosis was
significantly increased in tafazzin knockout cells compared to control cells (Fig. 4E).
In conclusion, both circulating and stem cell derived BTHS neutrophils exhibit elevated
intracellular calcium concentration, which promotes higher rates of NET formation in
response to calcium ionophore.

266 Elevated UPR signaling in BTHS patients

To better understand developmental changes in BTHS patient neutrophils, we 267 performed tandem mass tag (TMT) proteomic analysis of circulating neutrophils from 268 patients (n = 4 G-CSF-treated and n = 1 untreated, non-neutropenic patient), as well 269 as healthy controls (n = 5). We detected a total of 4056 proteins (Fig. S5A), including 270 271 306 proteins with significantly altered expression (p < 0.05), 91 of which had >2-fold difference. Ingenuity Pathway Analysis (IPA) revealed multiple significantly up- and 272 down-regulated pathways in BTHS neutrophils (Fig. 5A). Notably, the most strongly 273 enriched pathway in BTHS was oxidative phosphorylation (Fig. S5B), closely followed 274 by fatty acid oxidation (Fig. S5C), consistent with elevated mitochondrial load, as 275 detected with MitoTracker (Fig. 3C). Intriguingly, the second most enriched pathway 276 in BTHS neutrophils was the unfolded protein response (UPR), which was previously 277 implicated in neutrophil dysregulation in Tafazzin-KO mice [23]. Specifically, we 278 observed an upregulation of eight UPR proteins (Fig. 5B) and four proteins associated 279 with mitochondrial UPR (mt-UPR, Fig. 5C). These changes appeared to be GCSF-280 and neutropenia-dependent, as the only untreated, non-neutropenic patient in our 281 study consistently exhibited less pronounced alteration (sample BTHS5). Of note, 282

changes in the expression of mt-UPR proteins were more uniform among patients (Fig.S5D).

To confirm these changes, we quantified UPR protein abundance by Western blot (Fig. **5D**). To avoid confounding by G-CSF treatment, we used HSC-derived neutrophils from BTHS patients and HC, which are exposed to equivalent amounts of G-CSF over the 10 days of the differentiation protocol. Despite limited sample size, immunoblotting confirmed overexpression of IRE1 α , BiP, HSP60, and enhanced phosphorylation of eIF2 α (Fig. 5D, S5E).

UPR signaling is controlled by three upstream master regulators: ATF6, IRE1a and 291 PERK. We tested pharmacological inhibitors targeting all 3 of these pathways in 292 differentiation of neutrophils from HSC and found that inhibition of UPR regulator 293 294 PERK with GSK2606414 leads to a partial block in neutrophil differentiation, as evidenced by the reduced number of CD66b⁺CD15⁺ (DMSO = $51.12\pm15.79\%$ vs. 295 PERKi = 39.02±18.92%; p = 0.043) and CD11b^{hi} (DMSO = 39.43±14.19% vs. PERKi 296 = 24.58±14.56%; p = 0.043) neutrophils (Fig. 5E), reduced CD11b surface expression 297 (DMSO = 1.00±0.44 vs. PERKi = 0.77±0.38, p = 0.254); (Fig. S5F), and diminished 298 proliferation by the end of the differentiation process (DMSO = 27 ± 16 vs. PERKi = 299 9 ± 8 ; p = 0.0064); (Fig. S5G). ATF6 inhibitor (Ceapin A7) and IRE1 α inhibitor (4 μ 8C) 300 did not affect development at the concentration tested (data not shown). To further 301 investigate the role of the PERK pathway in neutrophil differentiation, we used the 302 PERK activator CCT020312 to increase the activity of this signaling pathway. Similarly 303 to PERK inhibition, PERK activation exhibited a trend towards partial reduction of 304 neutrophil differentiation, as evidenced by reduction in numbers of CD66b⁺CD15⁺ cells 305 $(DMSO = 61.73 \pm 9.39\% \text{ vs. } PERKa = 53.30 \pm 5.54\%; p = 0.185)$ and $CD11b^{hi}$ cells 306

307	$(DMSO = 54.00 \pm 10.67\% \text{ vs. } PERKa = 43.00 \pm 7.95\%; p = 0.153);$ (Fig. 5F), and
308	reduced CD11b surface expression (DMSO = 1.00 ± 0.18 vs. PERKa = 0.78 ± 0.08 , p =
309	0.067); (Fig. 5H) although neither were statistically significant. We also observed a
310	similar trend towards diminished proliferation by the end of the differentiation process
311	(DMSO = 41 ± 11 vs. PERKa = 32 ± 12 ; p = 0.301); (Fig. 5I), although again these
312	differences were not significant. Taken together, these results implicate dysregulation
313	of unfolded protein response in impairment of neutrophil development in BTHS.

315 **DISCUSSION**

Despite the prominence of neutropenia in BTHS patients, our understanding of the molecular and physiological causes of this phenomenon has been limited. Our study reveals that tafazzin has a cell-intrinsic role in regulating neutrophil differentiation and confirms a partial block in granulopoiesis in BTHS patients. We also show that tafazzin deficient neutrophils exhibit enhanced degranulation and elevated rate of NETosis. Finally, we confirm alterations in UPR signaling in BTHS neutrophils, which might be a contributing factor to the observed developmental and functional changes.

We observed a decrease in the number of mature neutrophils in BTHS bone marrow 323 samples. This is consistent with the original bone marrow examination by Barth [18] 324 325 (n=2) and subsequent work [12] that demonstrated hypocellularity in some, but not all, 326 BTHS patients. It remains unclear whether reduction in bone marrow neutrophils exists in a subset of patients and whether this is defined by the nature of the tafazzin mutation 327 328 or by extrinsic factors. The maturation deficiency largely manifests in later stages of neutrophil development, affecting metamyelocytes and band neutrophils. How this 329 leads to neutropenia, rather than simply a decrease in maturity of circulating 330 neutrophils, remains unexplained, and implies the involvement of additional extrinsic 331 332 factors.

We did not observe any evident hallmarks of early apoptosis in BTHS cultured neutrophils, which is reflected in largely unaltered proliferation rates. We showed that primary BTHS neutrophils exhibited a modest increase in annexin V binding, which is also induced by fMLP stimulation. Consistent with the conclusion of Kuijpers et al. [19] that increased binding of annexin V does not correlate with apoptosis, we propose that elevated PS in BTHS neutrophils results from increased neutrophil degranulation,

which is known to alter surface lipid composition and transiently expose PS [31, 32].
We conclude that neutropenia in BTHS patients is most likely not caused by
accelerated apoptosis.

Intriguingly, we also observed increased functional responses in tafazzin deficient 342 neutrophils. Both spontaneous and bacterial-induced degranulation were elevated in 343 344 patient neutrophils, although this was not observed when cells were cultured from tafazzin knockout stem cells. This discrepancy may be due to the fact that knockout 345 neutrophils display a more severe developmental delay than patient cells and the 346 propensity to hyperdegranulate is masked by developmental delays in synthesis of 347 granule components in KO neutrophils. Alternatively, unknown circulating factors in 348 patient plasma, such as inflammatory cytokines, may be priming circulating neutrophils 349 and lowering their degranulation threshold. 350

Tafazzin knockout neutrophils also show elevated rates of inflammatory NETotic cell 351 death in response to calcium mobilization, although this was not tested in circulating 352 BTHS patient neutrophils. Increased NET formation may lead to peripheral depletion 353 of neutrophils, possibly contributing to neutropenia. NET release is also a potent 354 inflammatory signal that activates macrophages and other immune cells [33, 34], 355 potentially lowering the threshold for acute and chronic inflammation [35, 36]. These 356 357 findings highlight a major knowledge gap on inflammatory processes in BTHS and suggest that inflammation should be further investigated as an etiological factor in 358 BTHS. 359

360 Several mechanisms can be proposed for enhanced granule exocytosis and NETosis 361 in tafazzin deficient neutrophils. First, we observed elevated levels of intracellular 362 calcium in BTHS cultured and primary neutrophils; Ca²⁺ flux promotes neutrophil

363 degranulation [27, 29] and NET release [30]. Mitochondria are known to regulate intracellular calcium stores [37] and this mechanism may be perturbed by alterations 364 in cardiolipin composition [10]. Secondly, it is known that ROS production, including 365 mtROS, can trigger the disassembly of filamentous actin (F-actin) [38-40], which is 366 needed for both mobilization of granules [41, 42] and NET formation [43]. We observed 367 elevated mtROS in BTHS neutrophils, suggesting that activation in BTHS may be 368 369 facilitated by ROS-induced actin degradation. Finally, degranulation is regulated by UPR sensors, which we found to be dysregulated in both primary and cultured BTHS 370 371 neutrophils. In a model of acute lung injury, ER stress triggered by the IRE1/XBP1 pathway promotes degranulation, and specific depletion of XBP1 in neutrophils 372 reduces granule secretion [44]. Similarly, in lupus, neutrophils exhibit elevated IRE1a 373 374 activity that was correlated with increased extracellular elastase activity [45]. These findings imply that fluctuations in UPR during the physiological turnover of neutrophils 375 could influence their inflammatory response. 376

In contrast to previous findings associating tafazzin deficiency with disruptions in 377 mitochondrial respiration [46-49], we found no defects in the basal and maximal 378 379 respiratory rates nor in the rate of ATP production in circulating BTHS neutrophils, although the interpretation of these findings is complicated by the fact that G-CSF-380 381 mobilized immature neutrophils have elevated mitochondrial content and activity [24]. Neutrophils differ from other cells in that they have fewer mitochondria per cell, which 382 has traditionally led to the belief that these cells primarily rely on glycolysis and are not 383 dependent on active mitochondria; however, recent advancements have highlighted 384 the significance of these organelles in neutrophil development and function [50, 51]. 385 Future studies should carefully examine mitochondrial metabolism in BTHS 386 387 progenitors.

388 Interestingly, our proteome analysis uncovered alternations in UPR and mtUPR pathways in BTHS neutrophils, which is in accordance with findings from Tafazzin-KO 389 mice [23]. UPR pathways were traditionally linked with protein misfolding in the ER; 390 391 however, recently these signaling modules were recognized to play a crucial role in regulation of immunity and inflammation [52]. For instance, experiments using HL-60 392 cells demonstrated that in vitro neutrophil differentiation relies on the stage-specific 393 394 expression of canonical UPR regulators. Notably, inhibition of these three proteins reduced the expression of CD11b and morphological differentiation, which we also 395 396 confirmed in our primary cell culture system using PERK inhibitor GSK2606414. Although the studies using *Tafazzin*-KO mice and HL-60 cells linked perturbations in 397 UPR with increased apoptosis [23, 53], as discussed above, we did not observe 398 399 differences in cell survival in cultured and circulating BTHS neutrophils. Neutropenia 400 is one of the symptoms of Wolcott-Rallison syndrome caused by mutations in the *EIF2AK3* gene, which encodes PERK [54], and heightened ER stress was reported in 401 neutropenias caused by mutations in *ELANE* and glucose-6-phosphate subunit α gene 402 (G6PC3); [55-57]. These findings collectively highlight the importance of tightly 403 regulated UPR in neutrophil development. 404

405 In summary, we confirmed a partial block in neutrophil maturation in BTHS patients, 406 resulting in generation of fewer mature neutrophils from stem cells. Despite alterations 407 in phenotype and function, BTHS neutrophils maintain their anti-microbial activity and display a hyperinflammatory phenotype. Potential causes of these changes could be 408 alterations in the UPR and calcium signaling pathways, which are currently recognized 409 410 as vital for neutrophil development and function. As neutropenia in BTHS patients has irregular patterns, disruption of neutrophil differentiation may be triggered under non-411 412 homeostatic conditions such as metabolic perturbations or other forms of cellular

- 413 stress. These conundrums imply the presence of underlying imbalances alongside
- 414 functional neutrophil precursors, necessitating further research to understand the
- 415 nuanced mechanisms at play.

417 MATERIALS AND METHODS

418 Human subjects and samples

The study was approved by NHS Research Ethics committee (permit number 419 09/H0202/52). Written informed consent was received from all patients and healthy 420 donors. The patient cohort consisted of 28 patients (27 male), while the controls 421 consisted of 31 individuals (27 male). Samples from some patients and healthy donors 422 423 were obtained multiple times. Patient genetic data (TAFAZZIN mutations) are listed in Table 1. Venous blood was collected in EDTA tubes (BD Biosciences). For shRNA 424 425 and CRISPR/Cas9 experiments, HSC were isolated from apheresis blood (NHSBT, Filton, Bristol, UK) with NHS REC approval (18/EE/0265). 426

427 Mouse model and experiments

All mouse experiments were performed in accordance with UK Home Office
regulations (Project License PP9886217), under the oversight of the Animal Welfare
and Ethical Review Board (AWERB) of the University of Glasgow.

The *Tafazzin* knockout mice were generated using G4 embryonic stem cells (isolated from C57BL/6Ncr x 129S6/SvEvTac F1 mice). After germline transmission of the targeted allele mice were bred for at least 10 generation to FVB/NCrl mice.

434 CD34⁺ HSC isolation and neutrophil culture

CD34⁺ HSCs were isolated either from peripheral blood of consented healthy donors
and BTHS patients or from apheresis blood and then cultured according to a modified
protocol of Naveh et al. [24]. In brief, peripheral blood mononuclear cells (PMBCs)
were isolated by density centrifugation using Histopaque®-1077 (Sigma-Aldrich)
according to manufacturer's instructions, followed by red cell lysis (55mM NH₄Cl,

0.137mM EDTA, 1mM KHCO₃, pH 7.5). CD34⁺ cells were enriched with a human 440 CD34 Microbead Kit (Miltenvi Biotec) according to manufacturer's protocol. For 441 peripheral blood HSCs, the cells were cultured in StemSpan[™] Hematopoietic Cell 442 Media (STEMCELLTM Technologies) supplemented with 1% (v/v) penicillin-443 streptomycin (P/S, Sigma-Aldrich) for the first 4 days and from day 5 of the culture, 444 cells were cultured in Iscove's Modified Dulbecco's Media (IMDM, Gibco[™]) 445 446 supplemented with 1% P/S and 10% (v/v) heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich). Cells isolated from apheresis blood were cultured in IMDM only. 447 448 Cytokines were added at the indicated concentrations and days of culture: stem cell factor (SCF, 50 ng/mL; day 0-5 of culture), Flt-3 ligand (50 ng/mL; day 0-5 of culture), 449 interleukin-3 (IL-3, 10 ng/mL; day 0-5 of culture), granulocyte-macrophage colony-450 451 stimulating factor (GM-CSF, 10 ng/mL; day 3-7 of culture), and granulocyte colonystimulating factor (G-CSF, 10 ng/mL; day 7-14 of culture). All inhibitors or activators 452 were added on day 3, 5, 7, 10 and 14 of the culture. All functional assays (unless 453 stated otherwise) were completed between Day 17 and 19 of culture. 454

455 CRISPR-mediated knockout of TAFAZZIN

456 CRISPR/Cas9 genome editing was performed on day 3 cultured neutrophils, by 457 nucleofection of ribonuclear particles, as described in [24]. gRNAs were designed 458 using Knockout Guide Design (Synthego). The following sgRNAs were used 459 (Synthego, modified sgRNA with EZ scaffold):

- 460 TAZ+154413511: UGCAGACAUCUGCUUCACCA;
- 461 TAZ-154413490: GCAGAUGUCUGCAGCUGCAG;
- 462 scrambled control #1: GCACUACCAGAGCUAACUCA;
- 463 scrambled control #2: GUACGUCGGUAUAACUCCUC.

464 shRNA-mediated knockdown of TAFAZZIN

465	shRNA knockdown was achieved using lentiviral transduction of day 3 cultured HSC.
466	HEK293T cells were transfected with psPAX2 and pMD2.G packaging vectors, along
467	with U6-based shRNA lentiviral vectors, with enhanced green fluorescent protein
468	(eGFP) as a marker (VectorBuilder Inc.). Virus was concentrated using Lenti- X^{TM}
469	Concentrator and added to the cultured neutrophils.

- 470 shRNA sequences:
- 471 shRNA 1: TGCTTCCTCAGTTACACAAAGCTCGAGCTTTGTGTAACTGAGGAAGCA
- 472 shRNA

2:

- 473 CTGTGGCATGTCGGAATGAATCTCGAGATTCATTCCGACATGCCACAG
- 475 n-t shRNA (scrambled control):

476 CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG

477 Flow cytometry analysis

The analysis was conducted as described in [25]. Briefly, cells were stained with 0.1% 478 Zombie[™] live/dead stain (BioLegend) and incubated for 10 min in the dark at RT. 479 Samples were washed, incubated in Fc receptor blocking solution Human TruStain 480 FcX[™] (BioLegend) diluted in MACS buffer (5 mM EDTA, 0.5% BSA in PBS) for 5 min, 481 and then a mix of primary antibodies in MACS was added followed by 30 min 482 incubation on ice. Samples then were washed twice with MACS buffer and fixed for 483 20 min with 2% formaldehyde in PBS. Cells were analyzed with BD LSRFortessa™ 484 X-20 Cell Analyzer. OneComp eBeadsTM (InvitrogenTM) were used as a single-color 485 compensation control. For Annexin V positivity, cells were stained with FITC-Annexin 486

V (BioLegend). At least 10,000 events were recorded per sample, and then analyzed
in FlowJo[™] software (version 9).

489 Western blot

Cells were lysed directly in 2x Bolt[™] LDS sample buffer (Invitrogen[™]) supplemented 490 with Halt[™] Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific[™]) and 491 heated for 10 min at 70°C. Samples were sonicated and then run on 4-12% Bolt[™] Bis-492 Tris Plus Mini Protein gels (Invitrogen[™]), followed by transfer onto Immobilon[®]-FL 493 PVDF membrane (MERCK), using a standard wet transfer protocol. The membrane 494 was blocked with 5% milk, incubated with primary antibodies overnight, and on the 495 following day with secondary antibodies for 1 h at RT. Blots were imaged using a LI-496 COR Odyssey[®] XF Imager. 497

498 PLB-985 cell culture and differentiation

PLB-985 were cultured in RPMI-1640 (Sigma-Aldrich) supplemented with P/S and
10% FBS. After lentiviral transduction, cells were differentiated by replacing the media
with RPMI-1640 with P/S, 2.5% FBS, 0.5% DMF, 1x Nutridoma-CS (Roche) and
culturing for 7 days.

503 Neutrophil isolation, oxidative burst, and NET formation

Neutrophils were isolated using the EasySep[™] Direct Human Neutrophil Isolation Kit 504 (STEMCELL[™] Technologies) as per the manufacturer's instructions. ROS production 505 with the luminol method, was quantified as previously described [58]. 506 Chemiluminescence was recorded in 2-minute intervals using a FLUOstar[®] Omega 507 plate reader (BMG LABTECH). NET assays were performed as described in [59]. Cells 508 were stimulated with 50nM PMA, 300nM fMLP, or 10µM A23187. NETs were stained 509

with SYTOX and SYTO dyes and imaged with either an EVOS® FL or Incucyte®
ZOOM imaging systems.

512 MPO ELISA

513 Plasma MPO was quantified using Human Myeloperoxidase DuoSet ELISA (R&D 514 Systems), according to manufacturer's instructions.

515 **Degranulation**

In experiments on circulating neutrophils, cells were stimulated with Nformylmethionine-leucyl-phenylalanine (fMLP, 300nM) for 30 min or *Streptococcus pyogenes* MGAS10270 for 40 min. For experiments on HSC-derived neutrophils, cells
were stimulated with A23187 (2.5µM) for 30 min. After stimulation, cells were stained
and fixed according to the flow cytometry protocol detailed above.

521 Bacterial killing assay

Neutrophils (2.5x10⁶) were resuspended in 500µL HBSS and combined with 5x10⁵ 522 Streptococcus pyogenes MGAS10270 bacteria [60] in HBSS supplemented with 2mM 523 524 CaCl₂, 2mM MgCl₂ and 10% pooled human serum (SEQUENS IVD). Samples were incubated at 37°C with atmospheric CO₂ levels on a rotator. Aliquots (50µL) of each 525 sample were taken immediately and thereafter every hour for 4 hours, and numbers 526 527 of viable bacteria enumerated following plating onto Todd-Hewitt agar plates supplemented with 0.5% (w/v) yeast extract and incubation overnight at 37°C, 5% 528 CO₂. Killing efficiency was calculated as number of colonies with neutrophils/number 529 of colonies with serum only. 530

531 Fluorescent immunohistochemistry and mouse whole blood analysis

Lung and spleen sections of germline *Tafazzin -/-* mice, were stained for neutrophil abundance with a neutrophil-specific calgranulin antibody, as previously described [61]. Tissue sections were imaged with a Leica DMI6000 inverted epifluorescence microscope and analysis was performed with ImageJ Fiji. For whole blood analysis, mice were tail vein bled, and blood sample analysis was performed using the Procyte DX Hematology analyzer.

538 Phagocytosis

Heat-killed *Streptococcus pyogenes* MGAS10270 (1x10⁹) were stained with pHrodoTM Phagocytosis Particle Labeling Kit for Flow Cytometry (InvitrogenTM) following the manufacturer's protocol. Neutrophils (2x10⁶) were resuspended in 500 μ L RPMI+Q and 2x10⁸ pHrodo-stained *Streptococcus pyogenes* were added for an MOI = 100. Suspensions were incubated with rotation at 37°C for 1 h, taking 100 μ I aliquots at multiple time points. Cells were then washed once and analyzed using BD LSRFortessaTM X-20 Cell Analyzer.

546 Seahorse metabolic flux analysis

547 Seahorse assay was performed according to the protocol in [24] using Seahorse 548 XFe96 microplates (Agilent) and Seahorse XF DMEM medium (Agilent).

549 Mitochondrial labelling

To label mitochondria, cells were incubated with 25 nM tetramethylrhodamine, ethyl ester, perchlorate (TMRE, InvitrogenTM), 5 μ M MitoSoxTM Red (InvitrogenTM), or 5 nM MitoTrackerTM green (InvitrogenTM) in prewarmed HBSS. Cells were incubated with each dye for 20 min at 37°C, washed with fresh media, resuspended in MACS buffer, and analyzed using BD LSRFortessaTM X-20 Cell Analyzer.

555 Intracellular calcium

Levels of intracellular Ca²⁺ were determined using the cell permeant calcium indicator
X-Rhod-1, AM (Invitrogen[™]). Cells were incubated with 500 nM X-Rhod-1 in RPMI for
1 h at 37°C, thoroughly washed with fresh media, resuspended in MACS buffer, and
analyzed with BD LSRFortessa[™] X-20 Cell Analyzer.

560 **Proteomics and bioinformatics analysis**

Isolated peripheral blood neutrophils from patients and controls were lysed and 561 labeled with tandem mass spectrometry reagents (Thermo Fisher), as previously 562 described [25]. Peptides were identified by nano LC-MS/MS with a Orbitrap[™] Fusion 563 Tribrid[™] Mass Spectrometer (Thermo Scientific[™]). Raw files were analyzed using 564 Proteome Discoverer[™] software v. 2 and cross-referenced against the human UniProt 565 database (human). The protein groups were reassessed by an in-house script which 566 initially selects a master protein by ID and quantitation metrics, then by annotation 567 quality of Uniprot accessions. Data were log₂ transformed and tested for statistical 568 significance using Welch's *t* test. IPA analysis was performed with a filter of P < 0.05569 570 to identify biological trends in the proteins that were statistically significant between conditions. PCAs were calculated using the PCA function in the FactoMineR package 571 and plotted using either ggplot (2D) or Plotly (3D). 572

573 Statistical analysis

The analysis was performed using GraphPad Prism 8 software. All the data are presented as mean ± SD. Unless stated otherwise, all "n" numbers represent the number of blood samples. Statistical analysis was completed, where appropriate, using t test when comparing two different samples, or one-way/two-way ANOVA where multiple samples were being examined.

579 **FIGURE LEGENDS**

580 Fig. 1. Tafazzin regulates neutrophil development

A. Wright-Giemsa staining of 8 bone marrow aspirates from BTHS patients. The 581 normal range (grey) represents values for healthy children. Samples from the same 582 patient, obtained at different ages, are marked in red. B. Myeloid:erythroid ratio for 583 samples analysed in A. C. Simplified overview of culture protocol for deriving 584 neutrophils from HSC. D. Growth curve of ex vivo HSC-derived neutrophil, n = 9 (HC), 585 8 (BTHS). E. Fold change of total cell count of HSC-derived neutrophils from day 3 to 586 day 17 of differentiation, n = 9 (HC), 8 (BTHS); ns – not significant. **F.** Percent of 587 CD66b⁺CD15⁺ neutrophils in HSC-derived cells at the end of differentiation, n = 9588 (HC), 8 (BTHS); * P \leq 0.05. **G.** CD11b surface expression of CD66b⁺CD15⁺ HSC-589 590 derived neutrophils at the end of differentiation, relative to averaged CD11b expression of control cells on a same day, n = 9 (HC), 8 (BTHS); * P \leq 0.05. **H.** CD11b 591 surface expression of control or tafazzin shRNA-treated CD66b⁺CD15⁺GFP⁺ HSC-592 derived neutrophils at the end of differentiation, relative to n-t shRNA control, n = 9593 (HC), 8 (BTHS); * P ≤ 0.05. I. Representative tafazzin Western blot of CRISPR/Cas9-594 edited HSC-derived neutrophils at the end of differentiation. J. Growth curve of 595 CRISPR/Cas9-edited HSC-derived neutrophils, n = 3 (experimental repeats). K. 596 CD11b surface expression of CD66b+CD15+ CRISPR/Cas9-edited HSC-derived 597 neutrophils at the end of differentiation, relative to scrambled gRNA control, n = 4; * P 598 ≤ 0.05. 599

600

Fig. S1. Impaired terminal differentiation and maturation of BTHS neutrophils ex *vivo*.

A. Representative image of BTHS patient bone marrow aspirate. B. Quantification of 604 average percentage of apoptotic (AV+PI-) and necrotic (AV+PI+) HSC-derived 605 neutrophils at the end of differentiation, n = 2 (HC), 3 (BTHS); ns – not significant. C. 606 607 Representative cytospins of HSC-derived neutrophils (day 17). D. Gating strategy for HSC-derived neutrophils (day 17). E. Average percentage of CD66b+CD15+CD11^{hi} 608 cells in live population of HSC-derived neutrophils at day 17, n = 9 (HC), 8 (BTHS) F. 609 Representative Western blot depicting level of tafazzin expression and graph showing 610 CD11b surface expression of PLB-985 cells transduced with lentivirus encoding non-611 targeting (n-t) or anti-TAFAZZIN shRNAs, n = 2 (experimental repeats). G. 612 613 Representative Western blot and graph depicting level of tafazzin expression level of GFP⁺ HSC-derived neutrophils transduced with lentivirus encoding non-targeting (n-t) 614 or anti-*TAFAZZIN* shRNAs, n = 3 (experimental repeats), * P \leq 0.05. **H.** Fold change 615 of total cell count of CRISPR/Cas9-edited HSC-derived neutrophils from day 3 to day 616 17 of differentiation matching tafazzin knockout cells to their relative controls, n = 4; * 617 P ≤ 0.05. 618

Fig. 2. Characterization of peripheral blood neutrophils from BTHS patients.

A. Surface expression of CD10 (left) and CD16 (right) in circulating neutrophils, n = 621 15 (HC, BTHS); * $P \le 0.05$. **B.** Surface expression of CD66b in circulating neutrophils, 622 n = 12 (HC), 15 (BTHS); *** P \leq 0.001. **C.** Surface expression of CD63 in unstimulated 623 (unstim) and fMLP-stimulated (300 nM) isolated neutrophils, n (unstim) = 29 (HC, 624 BTHS), n (fMLP) = 31 (HC, BTHS); ns – not significant, ** P \leq 0.01. **D.** Time-course of 625 CD66b surface expression in isolated neutrophils stimulated with Streptococcus 626 pyogenes, MOI = 100, n = 9 (HC), 7 (BTHS). E. MPO concentration in plasma, n = 20 627 (HC), 19 (BTHS); * $P \le 0.05$. F. Percentage of annexin V+ unstimulated neutrophils, n 628 = 6 (HC, BTHS); * $P \le 0.05$ G. Percentage of annexin V+ neutrophils, after stimulation 629 with 300 nM fMLP, n = 6 (HC, BTHS); ns – not significant. H. Area under the curve 630 631 (AUC) quantification of ROS, detected by luminol, n (unstim, PMA) = 10 (HC), 12 (BTHS), n (ConA) = 8 (HC), 10 (BTHS); ns – not significant. I. NET release in response 632 to 50 nM PMA, n = 7 (HC), 8 (BTHS); ns – not significant. J. Quantification of viable 633 Streptococcus pyogenes bacteria relative to "serum only" control, after incubation with 634 isolated neutrophils, n = 4 (HC, BTHS). 635

Fig. S2. Additional analyses of peripheral blood neutrophils

A. Surface expression of CD10 (left) and CD16 (right) in circulating neutrophils stratified according to G-CSF therapy; n = 15 (HC), 11 (BTHS+G-CSF), 4 (BTHS-G-CSF); * P ≤ 0.05, ns – not significant. **B.** Surface expression of CD62L (left) and CD101 (right) in circulating neutrophils, n = 15 (HC, BTHS); ns – not significant. **C.** Surface expression of CD66b in neutrophils stratified according to G-CSF treatment, n = 12 (HC), 10 (BTHS+G-CSF), 5 (BTHS-G-CSF); * P ≤ 0.05, **** P ≤ 0.0001. **D.** Representative epifluorescence images showing anti-calgranulin (green) and DAPI

(blue) staining of mouse lung and spleen (left) and quantification of average number of calgranulin-positive cells per mm² of section (right), n = 2 (mouse per genotype; the cells were counted from one transverse section through the middle part of the tissue). **E.** Percentage of neutrophils in mouse whole blood, n = 7 (WT), 8 (KO), ns - notsignificant. **F.** Phagocytosis time-course, measured by pHrodo fluorescence in isolated neutrophils, n = 3 (HC, BTHS).

Fig. 3. Mitochondrial perturbations in BTHS patient circulating neutrophils.

A. Average MitoTracker median fluorescence of isolated BTHS patient circulating 652 neutrophils normalized to HC (on the same day), n = 11 (HC, BTHS); *** P \leq 0.001. **B.** 653 Average percentage of neutrophils with low TMRE signal, n = 18 (HC), 17 (BTHS); * 654 $P \le 0.05$. **C.** Average rates of ATP production, basal respiration, maximal respiration, 655 656 and spare respiratory capacity, measured by Seahorse metabolic flux analyzer, n (ATP) = 6 (HC), 11 (BTHS), n (basal, maximal, spare respiration) = 6 (HC), 8 (BTHS); 657 ns – not significant. **D.** Percentage of MitoSOX-positive neutrophils n = 13 (HC, BTHS). 658 E. Percentage of MitoSOX-positive neutrophils, after stimulation with 300 nM fMLP, n 659 = 8 (HC), 9 (BTHS); ** P ≤ 0.01. 660

Fig. S3. Additional mitochondrial analyses in BTHS neutrophils.

A. Quantification of average mitoSOX median fluorescence of circulating neutrophils, n = 13 (HC, BTHS); ns – not significant. **B.** Quantification of average mitoSOX median fluorescence of circulating neutrophils stimulated with 300 nM fMLP, n = 8 (HC), 9 (BTHS), ns – not significant. **C.** Percentage of mitoSOX-positive HSC-derived neutrophils at the end of differentiation (D17), n = 3 (HC, BTHS); ns – not significant. **D.** Percentage of mitoSOX-positive HSC-derived neutrophils (D17), after stimulation with 300 nM fMLP, n = 3 (HC, BTHS); ns – not significant.

Fig. 4. Calcium homeostasis in BTHS neutrophils.

A. Average median fluorescence of calcium dye X-Rhod-1, normalized to HC (on the 671 same day), n = 11 (HC), 8 (BTHS); ** P \leq 0.01. **B.** Quantification of average median 672 fluorescence of X-Rhod-1 in HSC-derived BTHS neutrophils (D17), n = 3 (HC, BTHS); 673 * P \leq 0.05. **C.** An example of histogram depicting CD63 surface expression in HSC-674 675 derived neutrophils before and after stimulation with A23187 and surface expression of CD63 in unstimulated (unstim) and A23187-stimulated (2.5 µM) CRISPR/Cas9-676 edited HSC-derived neutrophils, n (unstim) = 4, n (A23) = 4; ns - not significant. **D.** 677 Quantification of NET release by CRISPR/Cas9-edited HSC-derived neutrophils 678 before or after stimulation with PMA (50nM) at 4 h post-stimulation, n = 4; ns - not 679 significant. E. Calculation of NET release by CRISPR/Cas9-edited HSC-derived 680 681 neutrophils before or after stimulation with A23187 (10 µM) at 4 h post-stimulation, n = 4; ns – no significant, * $P \le 0.05$. 682

Fig. 5. Elevated UPR signaling in BTHS neutrophils.

A. Plot showing significantly upregulated (positive Z-score, red) and downregulated 685 (negative Z-score, blue) IPA canonical pathways in circulating neutrophils from BTHS 686 patients. **B.** Heat map depicting upregulated UPR-related proteins in circulating BTHS 687 neutrophils, displayed as log2 fold change over HC, * P \leq 0.05, ** P \leq 0.01. **C.** Heat 688 map depicting upregulated mitochondrial UPR-related proteins in circulating BTHS 689 neutrophils, displayed as log2 fold change over HC, * P \leq 0.05, ** P \leq 0.01, *** P \leq 690 0.001, **** P ≤ 0.0001; B-C: *BTHS5* - non-neutropenic BTHS patient. **D.** Western blot 691 of selected UPR-related proteins in HC or BTHS patient HSC-derived neutrophils at 692 the end of differentiation (D17), n = 3 (HC, BTHS); asterisks indicate nonspecific 693 bands. E. Average percentage of HSC-derived neutrophils (CD66b⁺CD15⁺) and 694 mature neutrophils (CD66b+CD15+CD11bhi) at D17, after treatment with PERK 695 inhibitor (GSK2606414; 1 µM, added on day 3, 5, 7, 10, and 14 of culture) or vehicle 696 control (DMSO), n = 9 (DMSO, PERKi); * P \leq 0.05. **F.** Average percentage of HSC-697 derived neutrophils (CD66b⁺CD15⁺) and mature neutrophils (CD66b⁺CD15⁺CD11b^{hi}) 698 at D17, after treatment with PERK activator (CCT020312; 1 µM, added on day 3, 7, 699 700 10, and 14 of culture) or vehicle control (DMSO), n = 4 (DMSO, PERKa); ns - not701 significant.

702 Fig. S5. Elevated UPR signaling in BTHS neutrophils.

A. Volcano plot comparing BTHS and HC circulating neutrophil protein abundances, displayed as $-\log_{10} P$ -value and \log_2 fold change. **B.** Heat map depicting upregulated oxidative phosphorylation proteins identified with IPA, displayed as log2 fold change over HC, * P ≤ 0.05, ** P ≤ 0.01. **C.** Heat map depicting upregulated fatty acid oxidation proteins identified with IPA, displayed as log2 fold change over HC, * P ≤ 0.05, ** P ≤ 708 0.01; B-C: BTHS5 - non-neutropenic BTHS patient. D. Log₂ normalized abundance of mtUPR-related proteins identified by proteomics in circulating neutrophils, * $P \le 0.05$. 709 ** P \leq 0.01, *** P \leq 0.001, **** P \leq 0.0001. **E.** Quantification of UPR-related protein 710 711 expression in HSC-derived neutrophils at D17 of differentiation, n = 3 (HC, BTHS); ns – not significant, * $P \le 0.05$. **F.** Surface expression of CD11b in PERK-inhibited cells 712 (GSK2606414; 1 µM) or vehicle control (DMSO-treated) HSC-derived neutrophils at 713 D17 of differentiation, relative to averaged control (on a same day), n = 9 (DMSO, 714 PERKi); ns - not significant. G. Fold change in total cell count during HSC 715 716 differentiation, from day 3 to day 17, after treatment with PERK inhibitor (GSK2606414; 1µM) or vehicle control (DMSO), relative to averaged CD11b 717 expression of vehicle control cells on a same day, n = 9 (DMSO, PERKi); ** P ≤ 0.01 . 718 719 H. Surface expression of CD11b in PERK-activated cells (CCT020312; 1 µM) or 720 vehicle control (DMSO-treated) HSC-derived neutrophils at D17 of differentiation, relative to averaged control (on a same day), n = 4 (DMSO, PERKa); ns - not 721 722 significant. I. Fold change in total cell count during HSC differentiation, from day 3 to day 17, after treatment with PERK activator (CCT020312; 1 µM) or vehicle control 723 (DMSO), relative to averaged CD11b expression of vehicle control cells on a same 724 day, n = 4 (DMSO, PERKa); ns – no significant. 725

727 **DECLARATIONS**

728 Ethics approval and consent to participate

- 729 Patient blood samples were collected with approval from National Health Service
- 730 Research Ethics Committee (REC), 09/H0202/52. Apheresis and healthy control blood
- samples were collected under NHS REC 18/EE/0265.

732 Availability of data and materials

The research materials supporting this publication can be accessed bycontacting corresponding authors.

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [62] partner repository with the dataset identifier PXD052714.

738 Competing interests

The authors declare that they have no competing interests.

740 Author contributions

741 PZ, CR, DC, SG, FP, WG, KR, TP, EA and BA performed experiments and analyzed

742 data; **KF** organized access to and analysis of bone marrow aspirates; **DS** provided

mouse samples; **AHN** supervised bacterial experiments; **BA, CS and AT** conceived

- and supervised the study and acquired funding. **PZ** and **BA** wrote the manuscript.
- All authors read, provided input, and approved the final manuscript.

746 Funding

- This work was funded by Barth Syndrome Foundation (Idea Grants to BA and CS), by
- 748 Bristol & Weston Hospitals Charity (through funds provided by the COGENT Trust),

749 as well as MRC grant MR/R02149X/1 to BA. KF was funded by GW4-CAT Wellcome Trust Clinical PhD Fellowship. AT was funded by an NHS Blood and Transplant 750 (NHSBT) R&D grant (WP15-05) and a National Institute for Health Research Blood 751 and Transplant Research Unit (NIHR BTRU) in Red Blood Cell Products at the 752 University of Bristol in partnership with NHSBT (IS-BTU-1214-10032). KTR was 753 funded by a Wellcome Trust Dynamic Cell PhD studentship. DS was funded by CRUK 754 755 Scotland Institute core funding (A31287). The views expressed are those of the authors and not necessarily of the NHS, the NIHR or the Department of Health. 756

757 ACKNOWLEDGMENTS

We thank all the patients and blood donors for participating in our study, as well as nurses and clinical staff at the NHS Barth Syndrome Service and Bristol Children's Hospital. We acknowledge the assistance and support from Gillian Alexander, Maria Pelidis, Effie Chronopoulou, Rachel Schwartz, Olivia Gordon, Sally Turner, and Germaine Pierre. We also thank Jane Brittan for technical assistance with the bacterial experiments.

765 **REFERENCES**

- 1. Clarke, S.L., et al., *Barth syndrome*. Orphanet J Rare Dis, 2013. **8**: p. 23.
- Saric, A., et al., Barth Syndrome: From Mitochondrial Dysfunctions Associated with
 Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies. Front
 Genet, 2015. 6: p. 359.
- Taylor, C., et al., *Clinical presentation and natural history of Barth Syndrome: An overview.* J Inherit Metab Dis, 2022. 45(1): p. 7-16.
- Bione, S., et al., A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat
 Genet, 1996. 12(4): p. 385-9.
- 5. Paradies, G., et al., Role of Cardiolipin in Mitochondrial Function and Dynamics in Health
 and Disease: Molecular and Pharmacological Aspects. Cells, 2019. 8(7).
- 6. Greenwell, A.A., S.A. Tabatabaei Dakhili, and J.R. Ussher, *Myocardial disturbances of intermediary metabolism in Barth syndrome*. Front Cardiovasc Med, 2022. **9**: p. 981972.
- 7. Patil, V.A. and M.L. Greenberg, *Cardiolipin-mediated cellular signaling*. Adv Exp Med Biol,
 2013. 991: p. 195-213.
- Pizzuto, M. and P. Pelegrin, *Cardiolipin in Immune Signaling and Cell Death*. Trends Cell
 Biol, 2020. **30**(11): p. 892-903.
- 9. Dudek, J., *Role of Cardiolipin in Mitochondrial Signaling Pathways*. Front Cell Dev Biol,
 2017. 5: p. 90.
- 78410.Ghosh, S., et al., An essential role for cardiolipin in the stability and function of the785mitochondrial calcium uniporter. Proc Natl Acad Sci U S A, 2020. 117(28): p. 16383-78616390.
- Wilson, L.D., et al., *Higher IL-6 and IL6:IGF Ratio in Patients with Barth Syndrome*. J
 Inflamm (Lond), 2012. 9(1): p. 25.
- Steward, C.G., et al., Neutropenia in Barth syndrome: characteristics, risks, and
 management. Curr Opin Hematol, 2019. 26(1): p. 6-15.
- Mayadas, T.N., X. Cullere, and C.A. Lowell, *The multifaceted functions of neutrophils*.
 Annu Rev Pathol, 2014. **9**: p. 181-218.
- Amulic, B., et al., *Neutrophil function: from mechanisms to disease*. Annu Rev Immunol,
 2012. **30**: p. 459-89.
- Rankin, S.M., *The bone marrow: a site of neutrophil clearance*. J Leukoc Biol, 2010. 88(2):
 p. 241-51.
- Papadaki, H.A. and G.D. Eliopoulos, *Enhanced neutrophil extravasation may be a*contributing factor in the determination of neutropenia in patients with chronic idiopathic
 neutropenia of adults. Eur J Haematol, 1998. **61**(4): p. 272-7.
- B00 17. Duchene, J., et al., *Atypical chemokine receptor 1 on nucleated erythroid cells regulates* bematopoiesis. Nat Immunol, 2017. **18**(7): p. 753-761.
- Barth, P.G., et al., *An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes.* J Neurol Sci, 1983. **62**(1-3): p. 327-55.
- 80419.Kuijpers, T.W., et al., Neutrophils in Barth syndrome (BTHS) avidly bind annexin-V in the805absence of apoptosis. Blood, 2004. **103**(10): p. 3915-23.
- 806 20. Makaryan, V., et al., *The cellular and molecular mechanisms for neutropenia in Barth*807 syndrome. Eur J Haematol, 2012. 88(3): p. 195-209.
- Wang, S., et al., AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine
 Knockout Model of Barth Syndrome. Circ Res, 2020. 126(8): p. 1024-1039.
- Phoon, C.K., et al., *Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction.* J
 Am Heart Assoc, 2012. 1(2).

- Sohn, J., et al., A new murine model of Barth syndrome neutropenia links TAFAZZIN
 deficiency to increased ER stress-induced apoptosis. Blood Adv, 2022. 6(8): p. 25572577.
- 816 24. Naveh, C.A., et al., Neutrophils cultured ex vivo from CD34⁺ stem cells are immature and
 817 genetically tractable. 2024. 22(1): p. 526.
- 818 25. Rice, C.M., et al., *Hyperactive immature state and differential CXCR2 expression of* 819 *neutrophils in severe COVID-19.* Life Sci Alliance, 2023. **6**(2).
- Marini, O., et al., *Mature CD10(+) and immature CD10(-) neutrophils present in G-CSF- treated donors display opposite effects on T cells.* Blood, 2017. **129**(10): p. 1343-1356.
- Liu, X., et al., Increased Reactive Oxygen Species-Mediated Ca(2+)/CalmodulinDependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities
 and Impaired Contraction in Barth Syndrome. Circulation, 2021. 143(19): p. 1894-1911.
- 825 28. Feno, S., et al., Crosstalk between Calcium and ROS in Pathophysiological Conditions.
 826 Oxid Med Cell Longev, 2019. 2019: p. 9324018.
- Hann, J., et al., Calcium signaling and regulation of neutrophil functions: Still a long way
 to go. J Leukoc Biol, 2020. 107(2): p. 285-297.
- 829 30. Kenny, E.F., et al., *Diverse stimuli engage different neutrophil extracellular trap pathways*.
 830 Elife, 2017. 6.
- 831 31. Frasch, S.C., et al., *NADPH oxidase-dependent generation of lysophosphatidylserine*832 *enhances clearance of activated and dying neutrophils via G2A.* J Biol Chem, 2008.
 833 **283**(48): p. 33736-49.
- 834 32. Frasch, S.C., et al., *Phospholipid flip-flop and phospholipid scramblase 1 (PLSCR1) co-*835 *localize to uropod rafts in formylated Met-Leu-Phe-stimulated neutrophils*. J Biol Chem,
 836 2004. 279(17): p. 17625-33.
- 33. Apel, F., et al., *The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps*.
 Sci Signal, 2021. **14**(673).
- 839 34. Knackstedt, S.L., et al., *Neutrophil extracellular traps drive inflammatory pathogenesis in malaria*. Sci Immunol, 2019. 4(40).
- 84135.Wigerblad, G. and M.J. Kaplan, Neutrophil extracellular traps in systemic autoimmune842and autoinflammatory diseases. Nat Rev Immunol, 2023. 23(5): p. 274-288.
- 843 36. Castanheira, F.V.S. and P. Kubes, *Neutrophils and NETs in modulating acute and chronic*844 *inflammation.* Blood, 2019. **133**(20): p. 2178-2185.
- 845 37. Romero-Garcia, S. and H. Prado-Garcia, *Mitochondrial calcium: Transport and modulation of cellular processes in homeostasis and cancer (Review)*. Int J Oncol, 2019.
 847 54(4): p. 1155-1167.
- Sakai, J., et al., *Reactive oxygen species-induced actin glutathionylation controls actin dynamics in neutrophils*. Immunity, 2012. **37**(6): p. 1037-49.
- 850 39. Vorobjeva, N., et al., *Mitochondrial reactive oxygen species are involved in*851 *chemoattractant-induced oxidative burst and degranulation of human neutrophils in*852 *vitro*. Eur J Cell Biol, 2017. 96(3): p. 254-265.
- 40. Yadav, T., D. Gau, and P. Roy, *Mitochondria-actin cytoskeleton crosstalk in cell migration*.
 J Cell Physiol, 2022. 237(5): p. 2387-2403.
- 41. Jog, N.R., et al., *The actin cytoskeleton regulates exocytosis of all neutrophil granule*subsets. Am J Physiol Cell Physiol, 2007. **292**(5): p. C1690-700.
- 42. Mitchell, T., et al., *Primary granule exocytosis in human neutrophils is regulated by Rac-*dependent actin remodeling. Am J Physiol Cell Physiol, 2008. 295(5): p. C1354-65.
- 43. Metzler, K.D., et al., A myeloperoxidase-containing complex regulates neutrophil
 elastase release and actin dynamics during NETosis. Cell Rep, 2014. 8(3): p. 883-96.
- 86144.Hu, R., et al., Endoplasmic Reticulum Stress of Neutrophils Is Required for862Ischemia/Reperfusion-Induced Acute Lung Injury. J Immunol, 2015. 195(10): p. 4802-9.

- Sule, G., et al., Endoplasmic reticulum stress sensor IRE1alpha propels neutrophil
 hyperactivity in lupus. J Clin Invest, 2021. 131(7).
- 46. Lou, W., et al., Loss of tafazzin results in decreased myoblast differentiation in C2C12
 866 cells: A myoblast model of Barth syndrome and cardiolipin deficiency. Biochim Biophys
 867 Acta Mol Cell Biol Lipids, 2018. 1863(8): p. 857-865.
- 47. Dudek, J., et al., Cardiolipin deficiency affects respiratory chain function and organization
 in an induced pluripotent stem cell model of Barth syndrome. Stem Cell Res, 2013. 11(2):
 p. 806-19.
- 48. Hsu, P., et al., Cardiolipin remodeling by TAZ/tafazzin is selectively required for the
 initiation of mitophagy. Autophagy, 2015. 11(4): p. 643-52.
- Kagan, V.E., et al., Anomalous peroxidase activity of cytochrome c is the primary
 pathogenic target in Barth syndrome. Nat Metab, 2023. 5(12): p. 2184-2205.
- 50. Cao, Z., et al., *Roles of mitochondria in neutrophils*. Front Immunol, 2022. **13**: p. 934444.
- 876 51. Vorobjeva, N.V., et al., *Role of Mitochondria in the Regulation of Effector Functions of*877 *Granulocytes.* Cells, 2023. 12(18).
- S78 52. Grootjans, J., et al., *The unfolded protein response in immunity and inflammation*. Nat
 Rev Immunol, 2016. **16**(8): p. 469-84.
- 88053.Tanimura, A., et al., Mitochondrial Activity and Unfolded Protein Response are Required881for Neutrophil Differentiation. Cell Physiol Biochem, 2018. 47(5): p. 1936-1950.
- Lundgren, M., et al., *Practical management in Wolcott-Rallison syndrome with*associated hypothyroidism, neutropenia, and recurrent liver failure: A case report. Clin
 Case Rep, 2019. 7(6): p. 1133-1138.
- 885 55. Nanua, S., et al., Activation of the unfolded protein response is associated with impaired
 886 granulopoiesis in transgenic mice expressing mutant Elane. Blood, 2011. 117(13): p.
 887 3539-47.
- Sapra, A., et al., Effect of the unfolded protein response and oxidative stress on
 mutagenesis in CSF3R: a model for evolution of severe congenital neutropenia to
 myelodysplastic syndrome/acute myeloid leukemia. Mutagenesis, 2020. 35(5): p. 381389.
- Boztug, K., et al., A syndrome with congenital neutropenia and mutations in G6PC3. N
 Engl J Med, 2009. 360(1): p. 32-43.
- 89458.Harbort, C.J., et al., Neutrophil oxidative burst activates ATM to regulate cytokine895production and apoptosis. Blood., 2015. **126**(26): p. 2842-51. doi: 10.1182/blood-2015-89605-645424. Epub 2015 Oct 21.
- 89759.Amulic, B., et al., Cell-Cycle Proteins Control Production of Neutrophil Extracellular898Traps. Dev Cell, 2017. 43(4): p. 449-462.e5.
- 899 60. Beres, S.B. and J.M. Musser, Contribution of exogenous genetic elements to the group A
 900 Streptococcus metagenome. PLoS One, 2007. 2(8): p. e800.
- 901 61. Cela, D., et al., *PAD4* controls chemoattractant production and neutrophil trafficking in malaria. J Leukoc Biol, 2022. **111**(6): p. 1235-1242.
- 903 62. Perez-Riverol, Y., et al., *The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences*. Nucleic Acids Res, 2022. **50**(D1): p. D543905 D552.



FIGURE needRxiv preprint doi: https://doi.org/10.1101/2024.06.05.24307331; this version posted June 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under CC-BY-NC-ND 4.0 International license.





С





FIGURE 2(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



FIGURE week Rxiv preprint doi: https://doi.org/10.1101/2024.06.05.24307331; this version posted June 5, 2024. The copyright holder for this preprint which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



С





Ε



20000 I 15000 0 10000 5000 0 0 20 40 60 time (min)

F

FIGURE 3(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



D













FIGURE which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





FIGURE Solution provides the provided by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



TABLE 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Genetic information of patients

mutation	effect	exon/intron
c.9_10dupG	p.His4Alafs*130; frameshift	exon 1
c.51G>A	p.Trp17*; nonsense	exon 1
c.82_84delGTG	p.Val28del; deletion	exon 1
c.118A>G ¹	p.Asn40Asp; missense	exon 2
c.149T>C	p.Leu50Pro; missense	exon 2
c.182del	deletion/frameshift	exon 2
c.207C>G	p.His69GIn; missense	exon 2
c.216C>A	p.Cys72*; nonsense	exon 2
c.228_232del	deletion/frameshift	exon 2
c.239G>A	p.Gly80Glu or RNA splicing; missense	exon 3
c.281G>A1	p.Arg94His; missense	exon 3
c.346G>C	p.Gly116Arg; missense	exon 3
c.547_548insdel	insertion-deletion	exon 7
c.553A>G	new exonic splicing donor at codon Met185; p.Lys182GInfs*4; frameshift	exon 7
c.581G>A	p.Trp194*; nonsense	exon 7
c.583+5G>A	GTAAGG>GTAAAG; RNA splicing	intron 7
c.589G>A ²	p.Gly197Arg; missense	exon 8
c.589G>T	p.Gly197Trp; missense	exon 8
c.646+1del	deletion/frameshift	exon 8
c.809_812del	deletion/frameshift	exon 11
c.837_838delTC	p.Gln280Glyfs*30; frameshift	exon 11

¹Variant present in 2 patients

² Variant present in 4 patients

For 1 patient variant was unknown.

For more details on *TAFAZZIN* variants please refer to Human *TAFAZZIN* Gene Variant Database at: https://www.barthsyndrome.org/research/tafazzindatabase.html